Cold plasma.
Localized. Transient.
Broad-spectrum.
Aceso Plasma is a handheld, portable device that generates a transient, localized plasma field from ambient air. The multifactorial device outputs — including localized electric-field effects, charged particles, photons, and short-lived reactive species generated in situ — support wound-bed preparation and wound environment management. Based on FDA guidelines for thermal injury, the device does not cause irreversible thermal injury when used as directed.
How it works
Validated across
five institutions
Aceso Cold Plasma has been evaluated across five independent research institutions — including Wake Forest Institute of Regenerative Medicine, MedStar Georgetown Research Institute, and the US Army CCDC CBC. Investigational studies observed reduced microbial bioburden, accelerated wound healing in pre-clinical models, and a favorable safety profile at the treatment durations tested. Characterization of tissue effects and clinical outcomes is ongoing.
MedStar Georgetown Research Institute — demonstrated antimicrobial activity across 14+ pathogen species including antibiotic-resistant ESKAPE strains, comparable to Povidone Iodine at tested durations.
Wake Forest Institute of Regenerative Medicine — in vivo wound studies observed reduced wound contraction and accelerated re-epithelization in plasma-treated groups compared to untreated controls.
MedStar Georgetown — Burn Wound Study — porcine burn models showed reduced bioburden and no adverse impact on healing trajectory at the treatment parameters tested.
What makes Aceso Plasma different
Five core technology advantages that set Aceso Plasma apart from conventional wound care and disinfection approaches — in both clinical and field environments.
Multifactorial plasma outputs
Device-generated plasma produces transient, localized outputs — including reactive species generated in situ — that are scientifically recognized as capable of reducing microbial bioburden under defined experimental conditions.
Cold plasma technology
Operates at low temperatures — safely treating delicate tissues without thermal damage. Delivers power of plasma without the harmful side effects associated with heat-based or chemical approaches. Treatment parameters are designed to stay within a safe treatment window.
Operates from ambient air
The device draws from ambient air as its input — requiring no external gas tanks. Environmentally clean and logistically simple — critical for austere field deployment.
Portable power
Powered by AC or DC, the device operates across clinical settings and austere field environments without sacrificing output. Lightweight, hand-portable, and ready to deploy where it's needed most.
Versatile applications
Adaptable across wound healing, infected wounds, and equipment decontamination — in clinical, surgical, dermatological, and military field settings.
From research to
clinical reality.
Aceso Plasma has built a foundation of independently validated research, government-funded development, and strategic investment. Here's where we've been — and where we're going.
Development stage
Pre-Clinical Research
Completed 2022
SBIR Funding
Phase I & II complete
Series A Initial Tranche
Closed July 2025
V2 Development & FDA Submission
In progress · 2026
Clinical Trials & FDA Clearance
Upcoming
Aceso Plasma is an investigational device. The device is not currently cleared or approved for clinical use.
A track record of
delivering on commitments.
From the first government order to SBIR completion and the closing of our initial Series A tranche — every milestone delivered on time and on budget.
2020
January
Device Units Delivered to Government Agency
Delivered two Aceso Plasma Generator units to a government agency under a research and evaluation agreement — demonstrating early government interest in the technology and its potential field applications.
2020
Feb – Jun
SBIR Phase I & Phase II Awarded — $1.55M
Awarded $1.55M in combined SBIR Phase I and Phase II funding by the US Air Force to conduct research studies across wound healing, antimicrobial efficacy, burn wound care, and chemical agent decontamination.
2022
February
All Four SBIR Research Studies Completed
Completed four independent research studies — all on time and on budget — at Wake Forest Institute of Regenerative Medicine, MedStar Georgetown Research Institute, US Army CCDC CBC, and Edgewood Chemical Biological Center. Results established a comprehensive pre-clinical evidence base across wound healing, disinfection, burn care, and CBRN decontamination.
2025
July
Series A Initial Tranche Closed — Led by Stony Lonesome Group
Successfully closed the initial tranche of our Series A Preferred financing, led by Stony Lonesome Group — a proven early-stage defense and dual-use investor with 14 years of mission-focused investment. Funding supports the next phase of clinical development, regulatory advancement, and production development.
Read announcement on Soldier Systems DailyActive development
across four fronts.
Four parallel workstreams are underway in 2026 — advancing the device, the regulatory pathway, and the clinical leadership team simultaneously.
2026
June
Version 2 Prototypes — Device & Tips
Contract manufacturer Synectic is completing Version 2 prototypes for both the Aceso Plasma Generator and its interchangeable tips. Testing is scheduled to begin immediately upon completion — including spectroscopy, petri dish, and animal laboratory evaluations to validate performance improvements.
In progress2026
June
FDA Breakthrough Designation Submission
Preparing a Breakthrough Device Designation submission to the FDA. If received, Breakthrough Designation will provide clarity on the regulatory pathway, facilitate more frequent interaction with the FDA during development, and create significant marketing and credibility opportunities for the company.
Submission being prepared2026
May
Chief Medical Officer Appointed — Dr. Trip Johnson
Dr. Trip Johnson, a retired physician from the Joint Medical Augmentation Unit (JMAU), has joined Aceso Plasma as Chief Medical Officer. Dr. Johnson brings deep experience in military medicine and special operations medical support, and will chair the company's newly forming Physician Advisory Board.
Completed2026
2026
Physician Advisory Board — Formation Underway
Identifying candidates for a 2-3 physician Physician Advisory Board to be chaired by CMO Dr. Trip Johnson. The board will advise on strategic clinical issues, help communicate the unmet needs in current wound care, and guide Aceso's clinical positioning as the company advances toward FDA clearance.
Candidates being identifiedThe road to
FDA clearance.
The following milestones represent Aceso Plasma's current development roadmap. Timelines are targets and subject to change.
TBD
Upcoming
Clinical Trials — MedStar Georgetown Research Institute
Clinical trials are set to begin at MedStar Georgetown Research Institute for chronic wounds and ESKAPE pathogen-infected wounds — the primary FDA clearance pathway for the Aceso Plasma Generator.
TBD
Upcoming
ESKAPE Pathogen Animal Study
Infected wound healing animal study focused on ESKAPE pathogens — providing additional pre-clinical data to support the FDA De Novo application for the chronic wound care indication.
TBD
Upcoming
FDA Clearance — Chronic Wound Care Indication
Pursuing FDA De Novo clearance for the chronic wound care indication — the primary commercial pathway enabling clinical adoption across wound care centers, hospitals, and surgical settings.
TBD
Upcoming
Decon Chamber — Engineering & High-Level Disinfection Certification
Advancing the Aceso Decontamination Chamber from proof-of-concept prototype to engineered product, targeting FDA High-Level Disinfection Certification for use in military and medical settings.
Third-party recognition of our progress.
"Aceso Plasma Inc., which develops cold plasma medical and decontamination technology, today announced it has successfully closed a Series A Preferred funding round... led by Stony Lonesome Group, LLC. This milestone will support the next phase of clinical trials, regulatory advancement, and production development."
Interested in
where we're headed?
We are actively building relationships with accredited investors, clinical partners, and military collaborators. If you'd like to learn more about Aceso Plasma's development roadmap, we'd love to connect.